Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease?
Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease?
复制标题
DOI：
10.1007/s00251-010-0429-0
复制
发表时间：
2010-04-01
期刊：
影响因子：
3.2
通讯作者：
Weimann, Andreas
中科院分区：
文献类型：
--
作者：
Hoffmann, Christina;Hoffmann, Peter;Weimann, Andreas
甘露聚糖结合凝集素（MBL）通过结合微生物表面激活凝集素-补体途径，作为先天免疫防御的一部分。因此，MBL 2为炎症性肠病、溃疡性结肠炎（UC）和克罗恩病（CD）提供了一个有趣的候选基因。在我们的研究中，我们评估了MBL血清浓度和基因型用于CD和UC患者的诊断和分类目的。分析了98例CD患者和83例UC患者的MBL血清浓度。总共有82例炎性风湿性疾病患者和189名健康人作为对照。对所有研究受试者进行MBL 2多态性G54 D、G57 E和R52 C以及NOD 2（CARD 15）突变R702 W、G908 R和L1007 fsinsC的基因分型。队列之间的中位MBL血清浓度和MBL 2基因型分布均无显著差异。MBL血清浓度的测量对CD或UC的诊断没有帮助。
Mannan-binding lectin (MBL) activates the lectin-complement pathway as part of the innate immune defence by binding to the surface of microorganisms. Therefore, MBL2 presents an interesting candidate gene for the inflammatory bowel diseases, ulcerative colitis (UC) and Crohn's disease (CD). In our study, we evaluated the MBL serum concentrations and genotypes for diagnostic and classification purposes of patients with CD and UC. The MBL serum concentration was analysed in 98 CD patients and in 83 UC patients. In total, 82 patients with inflammatory rheumatic disorders and 189 healthy individuals served as controls. All study subjects were genotyped for the MBL2 polymorphisms G54D, G57E and R52C and the NOD2 (CARD15) mutations R702W, G908R and L1007fsinsC. Neither the median MBL serum concentration nor the MBL2 genotype distribution differed significantly between cohorts. Measurement of MBL serum concentrations offers no benefit for the diagnosis of CD or UC.